Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285996 | PMC |
| http://dx.doi.org/10.3390/jmahp13030033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EU-HTA Guidance for Clinical Validity: Misconceptions and Flawed Processes.
J Mark Access Health Policy
September 2025
CEReSS/UR3279-Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France; (L.B.); (P.A.).
The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?
J Mark Access Health Policy
March 2025
IQVIA, 1101 CT Amsterdam, The Netherlands;
The focus of manufacturers preparing for implementation of the EU HTA Regulation (HTAR) in 2025 has understandably been on their market access teams, and how they can be best equipped to adapt to this significant change. Considering the critical nature of market access in ensuring innovation reaches patients, it should be no surprise that the EU HTAR will have impacts far beyond this function. Here, we utilize published EU HTAR guidance, a pragmatic literature review, internal analysis, and insights from engagements with manufacturers, to outline some of the key cross-functional considerations arising from JSC and JCA, and how manufacturers should account for these in their EU HTAR readiness plans.
View Article and Find Full Text PDFGuidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World.
Clin Pharmacol Ther
April 2025
Boston Consulting Group, Zurich, Switzerland.
The value of a medicine is defined by its impact on patients, caregivers, health system, and society. A pharmaceutical company will generate evidence to demonstrate this value in various studies, including randomized clinical trials, non-interventional and observational studies, real-world data analyses, modeling, and simulation. The quality and strength of the evidence supporting a medicine's effectiveness, safety and product quality will drive decisions by healthcare system stakeholders for marketing authorization (regulatory authorities).
View Article and Find Full Text PDFAdvancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTA.
Int J Technol Assess Health Care
December 2024
Institute for Quality and Efficiency in Healthcare, Cologne, Germany.
Health Technology Assessment (HTA) in Europe has undergone significant evolution, culminating in the adoption of Regulation (EU) 2021/2282 on HTA (HTAR) aimed at fostering sustainable collaboration in HTA at the European Union (EU) level. The EUnetHTA 21 project, a 2-year initiative, was commissioned to address key methodological issues and prepare for the implementation of the HTAR. This commentary documents the outcomes of the EUnetHTA 21 project, focusing on Joint Clinical Assessments (JCAs), while analyzing challenges encountered and lessons learned for future collaboration under the HTAR.
View Article and Find Full Text PDFOpportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.
J Mark Access Health Policy
September 2024
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
National pricing and reimbursement agencies face growing challenges with complex health technologies, prompting European policy advancements. Beneluxa is a cross-country collaboration involving Belgium, the Netherlands, Luxemburg, Austria, and Ireland that aims to address sustainable access to medicines. In view of the soon-to-be-implemented EU HTA Regulation, insights and experiences from stakeholders with Beneluxa cross-country collaboration could provide possible transferable learnings.
View Article and Find Full Text PDF